NasdaqGS:PTCTBiotechs
Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?
PTC Therapeutics (PTCT) is back in focus after its PTC518 Huntington’s disease program received Fast Track designation, a regulatory milestone that can influence how investors view its rare neurology pipeline.
See our latest analysis for PTC Therapeutics.
At a share price of $78.59, PTC Therapeutics has a 90 day share price return of 8.67%, while its 1 year total shareholder return of 65% suggests stronger momentum over a longer window despite recent short term weakness. The Fast Track news...